HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study)

被引：0
作者：
Hasson, Hamid [1 ]
Galli, Laura [1 ]
Gallotta, Giulia [1 ]
Neri, Valentina [2 ]
Blanc, Pierluigi [3 ]
D'annunzio, Marco [4 ]
Morsica, Giulia [1 ]
Sollima, Salvatore [5 ]
Merli, Marco [1 ]
Lazzarin, Adriano [1 ,6 ]
Uberti-Foppa, Caterina [1 ]
机构：
[1] IRCCS Osped San Raffaele, Dept Infect Dis, I-20127 Milan, Italy
[2] L Spallanzani Natl Inst Infect Dis, Rome, Italy
[3] SS Annunziata Hosp, Dept Infect Dis, Florence, Italy
[4] Univ Bari, Inst Infect Dis, I-70121 Bari, Italy
[5] L Sacco Hosp Vialba, Dept Infect & Trop Dis, Milan, Italy
[6] Univ Vita Salute San Raffaele, Milan, Italy
来源：
NEW MICROBIOLOGICA | 2012年 / 35卷 / 04期
关键词：
HAART-simplification strategy; Anti-HCV drugs; LPV/r monotherapy; Tolerability of HIV/HCV treatments; LOPINAVIR-RITONAVIR MONOTHERAPY; MAINTENANCE THERAPY; 2; NUCLEOSIDES; HIV; ANTIRETROVIRALS; SUPPRESSION; MANAGEMENT;
D O I：
暂无
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week toxicity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naive to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.
引用
收藏
页码：469 / 474
页数：6
相关论文
共 50 条
  • [41] Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s
    Kiser, Jennifer J.
    Lu, Darlene
    Rosenkranz, Susan L.
    Morse, Gene D.
    DiFrancesco, Robin
    Sherman, Kenneth E.
    Butt, Adeel A.
    DRUGS IN R&D, 2017, 17 (04) : 557 - 567
  • [42] Biomarkers in a Cohort of HIV-Infected Patients Single- or Co-Infected with HTLV-1, HTLV-2, and/or HCV: A Cross-Sectional, Observational Study
    Caterino-de-Araujo, Adele
    Campos, Karoline R.
    Oliveira, Luanda M. S.
    Rigato, Paula O.
    VIRUSES-BASEL, 2022, 14 (09):
  • [43] Genotypic distribution and hepatic fibrosis among HIV/HCV co-infected individuals in Southern China: a retrospective cross-sectional study
    Zhou, Kali
    Hu, Fengyu
    Wang, Charles
    Xu, Min
    Lan, Yun
    Morano, Jamie P.
    Lemon, Stanley M.
    Tucker, Joseph D.
    Cai, Weiping
    BMC INFECTIOUS DISEASES, 2015, 15
  • [44] Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
    Valérie Martel-Laferrière
    Roy Nitulescu
    Joseph Cox
    Curtis Cooper
    Mark Tyndall
    Danielle Rouleau
    Sharon Walmsley
    Leo Wong
    Marina B. Klein
    BMC Infectious Diseases, 17
  • [45] Study of liver function tests in HIV-infected patients, with or without co-infection of HBV or HCV
    Hashemy, Seyed Isaac
    Rad, Robabeh Omidian
    Riazi, Zahra
    Hadi, Sadeghian Mohamamd
    CLINICAL BIOCHEMISTRY, 2011, 44 (13) : S126 - S127
  • [46] Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study
    Martel-Laferriere, Valerie
    Nitulescu, Roy
    Cox, Joseph
    Cooper, Curtis
    Tyndall, Mark
    Rouleau, Danielle
    Walmsley, Sharon
    Wong, Leo
    Klein, Marina B.
    BMC INFECTIOUS DISEASES, 2017, 17
  • [47] Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients:: the CORAL-1 multicentre pilot study
    Tural, C.
    Sola, R.
    Rubio, R.
    Santin, M.
    Planas, R.
    Quereda, C.
    Berenguer, J.
    Montes-Ramirez, M.
    Clotet, B.
    JOURNAL OF VIRAL HEPATITIS, 2007, 14 (10) : 704 - 713
  • [48] Measurement of hepatitis C virus RNA 12 weeks after treatment predicts sustained virological response in HIV-HCV co-infected patients
    Giron-Gonzalez, Jose-A
    Marquez, Maria-Jose
    Marquez, Mercedes
    Corchado, Sara
    Soto, Maria-Jose
    Martin-Aspas, Andres
    Montes De Oca, Monserrat
    Guerrero, Francisca
    Fernandez-Gutierrez, Clotilde
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2012, 30 (01): : 15 - 17
  • [49] Pilot study of interferon-α with and without amantadine for the treatment of hepatitis C in HIV co-infected individuals on antiretroviral therapy
    Sax, H
    Friedl, A
    Renner, E
    Steuerwald, MH
    Weber, R
    INFECTION, 2001, 29 (05) : 267 - 270
  • [50] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients
    Laguno, M
    Murillas, J
    Blanco, JL
    Martínez, E
    Miquel, R
    Sánchez-Tapias, JM
    Bargallo, X
    García-Criado, A
    de Lazzari, E
    Larrousse, M
    León, A
    Loncá, M
    Milinkovic, A
    Gatell, JM
    Mallolas, J
    AIDS, 2004, 18 (13) : F27 - F36
12345